BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
BioMarin Pharmaceutical reports 2019 executive compensation
By ExecPay News
Published: April 13, 2021
BioMarin Pharmaceutical reported fiscal year 2019 executive compensation information on April 13, 2021.
In 2019, six executives at BioMarin Pharmaceutical received on average a compensation package of $7.5M, a 24% increase compared to previous year.
Average pay of disclosed executives at BioMarin Pharmaceutical
Jean-Jacques Bienaim, Chief Executive Officer, received $18M in total, which increased by 18% compared to 2018. 63% of Bienaim's compensation, or $12M, was in stock awards. Bienaim also received $2.3M in non-equity incentive plan, $3.2M in option awards, $1.2M in salary, as well as $81K in other compensation.
For fiscal year 2019, the median employee pay was $190,917 at BioMarin Pharmaceutical. Therefore, the ratio of Jean-Jacques Bienaim's pay to the median employee pay was 96 to one.
Henry J. Fuchs, President, Worldwide R&D, received a compensation package of $7M, which increased by 21% compared to previous year. 61% of the compensation package, or $4.3M, was in stock awards.
Robert A. Baffi, President, Global Manufacturing amp; Technical Operations, earned $6.5M in 2019, a 47% increase compared to previous year.
Jeff Ajer, Executive Vice President, Chief Commercial Officer, received $6.3M in 2019, which increases by 40% compared to 2018.
Daniel Spiegelman, Chief Financial Officer, earned $5.2M in 2019, a 16% increase compared to previous year.
Brian R. Mueller, Chief Financial Officer, received $1.7M in 2019, which increases by 10% compared to 2018.
Related executives
Brian Mueller
BioMarin Pharmaceutical
Chief Financial Officer
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
Daniel Spiegelman
BioMarin Pharmaceutical
Chief Financial Officer
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
Robert Baffi
BioMarin Pharmaceutical
Former President of Global Manufacturing and Technical Operations
Henry Fuchs
BioMarin Pharmaceutical
President, Worldwide R&D
You may also like
Source: SEC filing on April 13, 2021.